Endometriosis: NICE approves new treatment option

Adrian O'Dowd, Adrian O’Dowd, O'Dowd A
BMJ (Clinical research ed.) · 2025 · vol. 389 , pp. r883 · doi:10.1136/bmj.r883 · PMID:40312061 · W4410004011
article OA: closed CC0
Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-13 ⓘ

NICE has approved a new treatment option for endometriosis, offering a novel therapeutic choice for patients with this condition.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-08-19 · read from full text ⓘ

The BMJ reports that the UK National Institute for Health and Care Excellence has approved linzagolix, marketed as Yselty, for treating endometriosis symptoms in reproductive-age patients who have failed prior medical or surgical interventions. This approval follows the drug's previous authorization for uterine fibroids and involves its use alongside hormonal add-back therapy to manage adverse effects. The guidance represents a significant expansion of treatment options for individuals with persistent symptoms despite standard care protocols. This paper is centrally about endometriosis — specifically the regulatory approval of a new GnRH antagonist treatment option by NICE.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Full text 909 characters · extracted from oa-doi-fallback · click to expand
News Endometriosis: NICE approves new treatment option BMJ 2025; 389 doi: https://doi.org/10.1136/bmj.r883 (Published 01 May 2025) Cite this as: BMJ 2025;389:r883- Adrian O’Dowd - London A drug that was approved last year for uterine fibroids is now available for patients of reproductive age who have previously had medical or surgical treatment for endometriosis. In final draft guidance published on 1 May the UK National Institute for Health and Care Excellence (NICE) has recommended linzagolix (marketed as Yselty) with hormonal add-back therapy for symptoms of endometriosis in this group.1 … Log in Log in using your username and password Log in through your institution Subscribe from £184 * Subscribe and get access to all BMJ articles, and much more. * For online subscription Access this article for 1 day for: £50 / $60/ €56 (excludes VAT) You can download a PDF version for your personal record.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2025) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

References (1)

Source provenance

europepmc
last seen: 2026-09-12T06:55:35.949492+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-09-12T06:51:11.505840+00:00
License: CC0 · commercial use OK